Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsDividends payablesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PharmaCyte Biotech (PMCB) Accumulated Expenses (2016 - 2026)

PharmaCyte Biotech (PMCB) has disclosed Accumulated Expenses for 16 consecutive years, with $445656.0 as the latest value for Q1 2026.

  • Quarterly Accumulated Expenses fell 37.18% to $445656.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $445656.0 through Jan 2026, down 37.18% year-over-year, with the annual reading at $2.5 million for FY2025, 242.1% up from the prior year.
  • Accumulated Expenses for Q1 2026 was $445656.0 at PharmaCyte Biotech, down from $520656.0 in the prior quarter.
  • The five-year high for Accumulated Expenses was $2.5 million in Q2 2025, with the low at $50100.0 in Q1 2022.
  • Average Accumulated Expenses over 5 years is $679713.4, with a median of $530331.0 recorded in 2022.
  • Peak annual rise in Accumulated Expenses hit 1446.8% in 2022, while the deepest fall reached 89.66% in 2022.
  • Over 5 years, Accumulated Expenses stood at $449855.0 in 2022, then skyrocketed by 126.33% to $1.0 million in 2023, then crashed by 30.54% to $707185.0 in 2024, then decreased by 26.38% to $520656.0 in 2025, then dropped by 14.4% to $445656.0 in 2026.
  • According to Business Quant data, Accumulated Expenses over the past three periods came in at $445656.0, $520656.0, and $595656.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.